Novartis Ag

Other

Alcon Research, Ltd.

Alcon Universal Ltd.

David Allen Marsh

Youqin Tian

Abbot F Clark

Billie M York

Bhagwati P Kabra

Gustav Graff

Michael A Kapin

Robert J Collier, Jr

Yoseph Yaacobi

Alan L Weiner

Shivalik Bakshi

Eliot Mark Slovin

Janet D Howie

Angela M Brodie

Theron R Rodstrom

Harry J Brodie

Larry Smith, Ii

Craig B Struble

David C Dahlin

Ii Larry Smith

The present invention concerns implantable ocular devices for the sustained release of medication to the eye, and methods for manufacturing and using such devices. In one embodiment, the present invention provides a device comprising: (a) a body comprising a matrix of a prostaglandin and a silicone; (b) a parylene coating on the outer surface of the body; and (c) one or more pores extending from the outer surface of the parylene coating to the outer surface of the body.

Punctal plugs and methods of delivering therapeutic agents

The present invention is directed to the treatment of disorders involving the accumulation of drusen, such as dry age-related macular degeneration and geographic atrophy via administration of therapeutically effective amounts of at least one monomeric or polymeric cyclodextrin.

Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen

Drug delivery film compositions containing a combination of a water-soluble, film-forming polymers and a fatty acid glyceride or ester are suitable for delivering ophthalmic drugs.

Bioerodible film for ophthalmic drug delivery

Disclosed is a method and apparatus for delivering a drug formulation to a human eye. The method includes the steps of inserting the apparatus below the Tenon's capsule and above the sclera at a point posterior to the limbus of the eye and injecting the drug formulation to form a drug depot on an outer surface of the sclera. The apparatus includes a cannula having a distal portion, a proximal portion, and a bend separating the distal portion and the proximal portion. The distal portion has a radius of curvature substantially equal to a radius of curvature of the globe of the eye. A tangent of the distal portion at the bend is disposed at an angle no more than about 56 degrees with respect to the proximal portion.

Sub-tenon drug delivery

This invention relates to ester derivatives of 4-hydroxy-4-androstene-3,17-dione (4-OH-4-A), including the acetate, heptanoate, dodecanoate, hemisuccinate and benzoate esters of 4-OH-4-A. This invention also relates to a method of using the esters in the inhibition of estrogen biosynthesis.

Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for

Growing community of inventors

Fort Worth, TX, United States of America

David Allen Marsh